Skip to main content
Home
OUR XCHANGES
LIFE SCIENCES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY MANUFACTURING
CNS DISCOVERY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY MANUFACTURING
ANTIBODY THERAPEUTICS
CNS DISCOVERY
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
LIFE SCIENCES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY MANUFACTURING
CNS DISCOVERY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY MANUFACTURING
ANTIBODY THERAPEUTICS
CNS DISCOVERY
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Sponsorship Enquiry
Register For Free
Home
OUR XCHANGES
LIFE SCIENCES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
ANTIBODY MANUFACTURING
CNS DISCOVERY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY MANUFACTURING
ANTIBODY THERAPEUTICS
CNS DISCOVERY
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Jeremy Linsley
Co-Founder/CSO,
Stealth Mode Biotech
Sessions
10-Sep-2026
09:05 – 10:05
Disease heterogeneity as a barrier to reliable biomarker development in CNS therapeutics
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
)
